Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 3, 2006, Pages 225-231

  Nowakowski, Grzegorz S ^a   Witzig, Thomas E ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

CD20; Ibritumomab tiuxetan; NHL; Radioimmunotherapy; Tositumomab

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GROWTH FACTOR; IBRITUMOMAB TIUXETAN; METHOTREXATE; PREDNISONE; RITUXIMAB; THYROID HORMONE; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE LEUKEMIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; HYPOTHYROIDISM; INFECTION; LYMPHOMA CELL; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RADIOIMMUNOTHERAPY; REVIEW; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 33745443343     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
2. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric an ti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
3. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
5. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo). 2005;46:241-248.
6. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545-3557.
7. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
8. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
9. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med. 1998;39(8 suppl):21S-27S.
10. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8 suppl):14S-20S.
11. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma. with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
12. Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med. 1998;39(8 suppl):1S.
13. Koral KF, Dewaraja Y, Li J, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464.
14. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
15. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
16. Stagg R, Wahl RL, Estes J, Kaminski M. Phase I/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): final results. Proc Am Soc Clin Onocl. 1998;17:39a. Abstract 150.
17. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
18. Fehrenbacher L, Radford JA, Kaminski M, Kroll S, Vose J. Patient-specific dosing of BexxarTM is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors. Proc Am Soc Clin Onocl. 2001;20(pt 1 of 2):287a. Abstract 1144.
19. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
20. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
21. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
22. Davis T, Kaminski M, Leonard J, et al. Results of a randomized study of Bexx-arTM (tositumomab and iodine 131 tositumomab) versus unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma. Blood. 2001;98 (suppl 1 pt 1):843a.
23. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of 90Y-labeled ibritumomab tiuxetan (Zevalin) radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clinl Oncol. 2002;20:2453-2463.
24. Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(4):1244-1253.
25. Horning SJ, Lucas J, Younes A, et al. Iodine I 131 tositumomab non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center phase II study. Blood. 2000;96(11 pt 1 of 2):508a.
26. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
27. Zelenetz A, Saleh M, Vose J, Younes A, Kaminski M. Patients with transformed low grade lymphoma attain durable responses following out-patient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [abstract]. Blood. 2002;100:357.
28. Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood. 2004;104(11):41a. Abstract 130.
29. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3885-3890.
30. Cooney J, Stiff P, Kaminski M. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Bone Marrow Transplant. 2002;29:523-525.
31. Kaminski M, Estes J, Zasadny K, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
32. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23):7985-7993.
33. Wiseman G, Witzig T. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results. Blood. 2002;100(11):358a. Abstract 1387.